Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV000200507 | SCV000254806 | uncertain significance | Hereditary diffuse gastric adenocarcinoma | 2024-01-10 | criteria provided, single submitter | clinical testing | This sequence change replaces threonine, which is neutral and polar, with alanine, which is neutral and non-polar, at codon 414 of the CDH1 protein (p.Thr414Ala). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with CDH1-related conditions. ClinVar contains an entry for this variant (Variation ID: 216586). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
| Ambry Genetics | RCV000565479 | SCV000666323 | uncertain significance | Hereditary cancer-predisposing syndrome | 2016-09-21 | criteria provided, single submitter | clinical testing | The p.T414A variant (also known as c.1240A>G), located in coding exon 9 of the CDH1 gene, results from an A to G substitution at nucleotide position 1240. The threonine at codon 414 is replaced by alanine, an amino acid with similar properties. This variant was not reported in population based cohorts in the following databases: Database of Single Nucleotide Polymorphisms (dbSNP), NHLBI Exome Sequencing Project (ESP), and 1000 Genomes Project. In the ESP, this variant was not observed in 6498 samples (12996 alleles) with coverage at this position. To date, this alteration has been detected with an allele frequency of approximately 0.0004% (greater than 240000 alleles tested) in our clinical cohort. This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
| CHEO Genetics Diagnostic Laboratory, |
RCV003491947 | SCV004240419 | uncertain significance | Breast and/or ovarian cancer | 2023-04-25 | criteria provided, single submitter | clinical testing |